[go: up one dir, main page]

AU2001264559A8 - Cancer gene determination and therapeutic screening using signature gene sets - Google Patents

Cancer gene determination and therapeutic screening using signature gene sets

Info

Publication number
AU2001264559A8
AU2001264559A8 AU2001264559A AU6455901A AU2001264559A8 AU 2001264559 A8 AU2001264559 A8 AU 2001264559A8 AU 2001264559 A AU2001264559 A AU 2001264559A AU 6455901 A AU6455901 A AU 6455901A AU 2001264559 A8 AU2001264559 A8 AU 2001264559A8
Authority
AU
Australia
Prior art keywords
gene
determination
signature
therapeutic screening
sets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264559A
Other versions
AU2001264559A1 (en
Inventor
Steve Horrigan
Reinhard Ebner
Meena Augustus
Zoe Weaver
Kenneth C Carter
Greg Endress
Daniel R Soppet
Paul E Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Data Inc
Original Assignee
Avalon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals Inc filed Critical Avalon Pharmaceuticals Inc
Publication of AU2001264559A8 publication Critical patent/AU2001264559A8/en
Publication of AU2001264559A1 publication Critical patent/AU2001264559A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001264559A 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets Abandoned AU2001264559A1 (en)

Applications Claiming Priority (85)

Application Number Priority Date Filing Date Title
US20953100P 2000-06-05 2000-06-05
US20947300P 2000-06-05 2000-06-05
US60/209,473 2000-06-05
US60/209,531 2000-06-05
US23313300P 2000-09-18 2000-09-18
US23361700P 2000-09-18 2000-09-18
US60/233,133 2000-09-18
US60/233,617 2000-09-18
US23400900P 2000-09-20 2000-09-20
US23403400P 2000-09-20 2000-09-20
US23405200P 2000-09-20 2000-09-20
US60/234,009 2000-09-20
US60/234,034 2000-09-20
US60/234,052 2000-09-20
US23450900P 2000-09-22 2000-09-22
US23456700P 2000-09-22 2000-09-22
US60/234,509 2000-09-22
US60/234,567 2000-09-22
US23492300P 2000-09-25 2000-09-25
US23513400P 2000-09-25 2000-09-25
US23508200P 2000-09-25 2000-09-25
US23492400P 2000-09-25 2000-09-25
US23507700P 2000-09-25 2000-09-25
US23528000P 2000-09-25 2000-09-25
US60/235,077 2000-09-25
US60/234,923 2000-09-25
US60/235,280 2000-09-25
US60/235,134 2000-09-25
US60/234,924 2000-09-25
US60/235,082 2000-09-25
US23563800P 2000-09-26 2000-09-26
US23563700P 2000-09-26 2000-09-26
US60/235,637 2000-09-26
US60/235,638 2000-09-26
US23586300P 2000-09-27 2000-09-27
US23572000P 2000-09-27 2000-09-27
US23571100P 2000-09-27 2000-09-27
US23584000P 2000-09-27 2000-09-27
US60/235,720 2000-09-27
US60/235,863 2000-09-27
US60/235,840 2000-09-27
US60/235,711 2000-09-27
US23602800P 2000-09-28 2000-09-28
US23603200P 2000-09-28 2000-09-28
US23603300P 2000-09-28 2000-09-28
US23611100P 2000-09-28 2000-09-28
US23603400P 2000-09-28 2000-09-28
US23610900P 2000-09-28 2000-09-28
US60/236,032 2000-09-28
US60/236,111 2000-09-28
US60/236,028 2000-09-28
US60/236,033 2000-09-28
US60/236,109 2000-09-28
US60/236,034 2000-09-28
US23689100P 2000-09-29 2000-09-29
US23684200P 2000-09-29 2000-09-29
US60/236,842 2000-09-29
US60/236,891 2000-09-29
US23729400P 2000-10-02 2000-10-02
US23717300P 2000-10-02 2000-10-02
US23717200P 2000-10-02 2000-10-02
US23731600P 2000-10-02 2000-10-02
US23729500P 2000-10-02 2000-10-02
US23727800P 2000-10-02 2000-10-02
US60/237,173 2000-10-02
US60/237,294 2000-10-02
US60/237,172 2000-10-02
US60/237,278 2000-10-02
US60/237,295 2000-10-02
US60/237,316 2000-10-02
US23760800P 2000-10-03 2000-10-03
US23742500P 2000-10-03 2000-10-03
US23760400P 2000-10-03 2000-10-03
US23759800P 2000-10-03 2000-10-03
US23760600P 2000-10-03 2000-10-03
US60/237,606 2000-10-03
US60/237,598 2000-10-03
US60/237,608 2000-10-03
US60/237,425 2000-10-03
US60/237,604 2000-10-03
US24486700P 2000-11-01 2000-11-01
US24508400P 2000-11-01 2000-11-01
US60/244,867 2000-11-01
US60/245,084 2000-11-01
PCT/US2001/010838 WO2001094629A2 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets

Publications (2)

Publication Number Publication Date
AU2001264559A8 true AU2001264559A8 (en) 2001-12-17
AU2001264559A1 AU2001264559A1 (en) 2001-12-17

Family

ID=27586968

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264559A Abandoned AU2001264559A1 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets

Country Status (5)

Country Link
EP (1) EP1358349A2 (en)
JP (1) JP2004509612A (en)
AU (1) AU2001264559A1 (en)
CA (1) CA2411601A1 (en)
WO (1) WO2001094629A2 (en)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777537B1 (en) 1996-02-22 2004-08-17 Forsyth Dental Infirmary For Children Osteoclast proton pump subunit
US20040219569A1 (en) 1999-07-06 2004-11-04 Fruma Yehiely Gene identification method
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020147143A1 (en) * 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2329851T3 (en) 1998-06-01 2009-12-01 Agensys, Inc. NEW TRANSMEMBRANABLE ANTIGENS EXPRESSED IN HUMAN CANCER AND USING THEMSELVES.
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1621620A3 (en) * 1999-09-01 2006-05-10 Genetech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
CA2386858C (en) 1999-10-28 2011-12-20 Agensys, Inc. 36p6d5: secreted tumor antigen
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
JP2003528886A (en) 2000-03-24 2003-09-30 デューク・ユニバーシティ Characterization of CRP94-ligand interactions and related purification, screening and therapeutic methods
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
CA2405431A1 (en) * 2000-03-31 2001-10-11 Gene Logic, Inc. Gene expression profiles in esophageal tissue
NZ521786A (en) * 2000-03-31 2004-07-30 Aventis Pharma Inc NFIF-14b and NFIF-7a (nuclear factor kappa B inducing factor) polypeptides and nulciec acids and their use in compositions for inhibiting inflammation
CA2585822A1 (en) * 2000-06-02 2001-12-13 Genentech, Inc. Breast, rectal, colon and lung tumour marker pro19628 polypeptide and encoding nucleic acid
US6524819B1 (en) * 2000-07-11 2003-02-25 Incyte Genomics, Inc. Down syndrome critical region 1-like proteins
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2416732C (en) 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
CA2417676A1 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Sequences for integrin alpha-8
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
US7081344B2 (en) 2000-11-30 2006-07-25 Millennium Pharmaceuticals, Inc. Methods for screening compounds that bind human COE-2
EP1410035A2 (en) * 2000-12-08 2004-04-21 EOS Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20020137184A1 (en) * 2000-12-20 2002-09-26 Pe Corporation (Ny) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030194702A1 (en) * 2000-12-22 2003-10-16 Engelhard Eric K. Novel compositions and methods for cancer
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
CA2437750A1 (en) * 2001-02-08 2002-08-15 Tularik Inc. Prc17: an amplified cancer gene
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
CA2439630A1 (en) * 2001-03-23 2002-10-03 Agy Therapeutics Use of biomolecular targets in the treatment and visualization of brain tumors
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1795597B1 (en) * 2001-05-31 2010-08-18 Chiba-Prefecture Nucleic acids isolated from a neuroblastoma
EP1402058A4 (en) * 2001-06-05 2006-02-01 Exelixis Inc DGK AS MODULATORS OF THE P53 ACTION MECHANISM AND METHODS OF USE
KR100603488B1 (en) * 2001-06-20 2006-07-24 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
JP2005505271A (en) 2001-09-06 2005-02-24 アジェンシス, インコーポレイテッド Nucleic acids and corresponding proteins given the name STEAP-1 useful in the treatment and detection of cancer
WO2003025199A2 (en) * 2001-09-18 2003-03-27 Millennium Pharmaceuticals, Inc. Mid 4460, a human tyrosine phosphatase family member and uses therefor
WO2003035857A1 (en) * 2001-10-22 2003-05-01 Bayer Healthcare Ag Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003046581A2 (en) * 2001-11-27 2003-06-05 Oxford Glycosciences (Uk) Ltd Methods for diagnosis and treatment of epithelial-derived cancers,such as colorectal cancers and kidney cancers
JP2005514940A (en) * 2002-01-18 2005-05-26 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 1435 molecule, 559 molecule, 34021 molecule, 44099 molecule, 25278 molecule, 641 molecule, 260 molecule, 55089 molecule, 21407 molecule, 42032 molecule, 46656 molecule, 62553 molecule, 302 molecule, 323 molecule, 12303 molecule, 985 molecule, 13237 molecule And compositions for the treatment of urological diseases using, 13601, 18926, 318, 2058 or 6351 molecules
WO2003064451A2 (en) * 2002-02-01 2003-08-07 Beth Israel Deaconess Medical Center, Inc. MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE
JP2005518821A (en) * 2002-03-06 2005-06-30 アバロン ファーマシューティカルズ Cancer-related genes as targets for chemotherapy
US20030215852A1 (en) * 2002-04-01 2003-11-20 Wyeth Novel pancortin-Pablo protein interactions and methods of use thereof
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
CA2413475C (en) 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
EP1510587B1 (en) * 2002-05-21 2011-07-13 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
EP1365247A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3)
EP1365244A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)
EP1507553A2 (en) 2002-05-29 2005-02-23 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Pancreas-specific proteins
WO2003105758A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
AU2003247564A1 (en) * 2002-06-12 2003-12-31 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2004003564A2 (en) * 2002-06-26 2004-01-08 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
GB0216727D0 (en) 2002-07-17 2002-08-28 Univ Cambridge Tech Genes
WO2004016784A1 (en) * 2002-08-06 2004-02-26 Genox Research, Inc. Protease inhibitor
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
DE60329115D1 (en) * 2002-09-27 2009-10-15 Dainippon Sumitomo Pharma Co TUMORANT PROPERTIES AND USE THEREOF
DE60325628D1 (en) 2002-09-30 2009-02-12 Oncotherapy Science Inc GENES AND POLYPEPTIDES IN CONNECTION WITH HUMAN PANCREATIC CARCINOMAS
WO2005090991A1 (en) * 2004-03-24 2005-09-29 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1551443A2 (en) * 2002-10-14 2005-07-13 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis
WO2004038411A2 (en) * 2002-10-24 2004-05-06 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
AU2003292737A1 (en) * 2002-12-24 2004-07-22 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US7425624B1 (en) * 2003-01-21 2008-09-16 Mayo Foundation For Medical Education And Research Sulfotransferase 1A3 sequence variants
WO2004066941A2 (en) * 2003-01-24 2004-08-12 Bayer Pharmaceuticals Corporation Expression profiles for colon cancer and methods of use
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004073656A2 (en) 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DE10309729A1 (en) * 2003-02-26 2004-09-16 Hinzmann, Bernd, Dr. Human nucleic acid sequences from bladder cancer
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP1605044A4 (en) * 2003-03-10 2006-12-06 Japan Science & Tech Agency MARKER FOR DETECTION OF MESENCHYMAL STEM CELL AND METHOD FOR DISTINGUISHING MESENCHYMAL STEM CELL USING A MARKER
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
FR2853909A1 (en) * 2003-04-16 2004-10-22 Galderma Res & Dev Using polynucleotide probes based on the DPYSL3 gene (Dihydropyrimidinase-like 3), for diagnosis of psoriasis, or predisposition, and in screening for antipsoriatic agents
EP1639129A2 (en) * 2003-05-21 2006-03-29 F. Hoffmann-La Roche Ag Markers for lxr activation
CA2527321A1 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CA2528549A1 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
CN105316405A (en) * 2003-07-17 2016-02-10 环太平洋生物技术有限公司 Markers for detection of gastric cancer
WO2005013893A2 (en) * 2003-07-24 2005-02-17 Avalon Pharmaceuticals, Inc. Cancer related genes
JP4643450B2 (en) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス Cancer high expression gene
AU2004265662B2 (en) * 2003-08-14 2010-12-16 Exelixis, Inc. UPs as modifiers of the beta catenin pathway and methods of use
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
WO2005059108A2 (en) * 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
AU2004298604B2 (en) * 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
GB0329997D0 (en) * 2003-12-24 2004-01-28 Cancer Rec Tech Ltd Methods for detecting neoplasia and markers thereof
US7264841B2 (en) 2004-01-21 2007-09-04 Linda Kalustian Lester Savory gluten-free foods
WO2005076005A2 (en) * 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
TW200600785A (en) 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
JP2007532111A (en) * 2004-04-06 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Orphan receptor tyrosine kinase as a target in breast cancer
JPWO2005097204A1 (en) 2004-04-09 2008-02-28 武田薬品工業株式会社 Cancer preventive / therapeutic agent
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1743038A4 (en) * 2004-05-04 2007-11-21 Bayer Healthcare MN / CA IX / CA9 AND PROGNOSIS OF KIDNEY CANCER
AU2012200098B2 (en) * 2004-05-11 2014-05-08 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumour diagnosis and therapy
AU2013206612B2 (en) * 2004-05-11 2016-04-28 Biontech Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004023187A1 (en) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
EP1774043A4 (en) * 2004-05-28 2009-09-02 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING AND TREATING CANCER
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
WO2005118879A2 (en) 2004-06-04 2005-12-15 Arcturus Bioscience, Inc. Identification of tumors
CN101258249A (en) * 2004-06-24 2008-09-03 维里德克斯有限责任公司 Methods and reagents for detecting melanoma
US20080254031A1 (en) * 2004-09-09 2008-10-16 Exonhit Therapeutics Sa Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
KR20070090156A (en) * 2004-10-13 2007-09-05 에이 앤드 지 파마슈티컬즈, 인코포레이티드 Autocline Growth Factor Receptors and Methods
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
JP5222559B2 (en) 2004-10-15 2013-06-26 シアトル ジェネティックス, インコーポレイテッド Anti-CD70 antibodies and uses thereof for the treatment and prevention of cancer and immune disorders
WO2006053442A1 (en) * 2004-11-22 2006-05-26 Diagnocure Inc. Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
JP2006174731A (en) * 2004-12-21 2006-07-06 Seikagaku Kogyo Co Ltd Translocation agent and method for detecting canceration of tissue
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene, protein encoded thereby, expression vector comprising the same and cells transformed with the vector
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
KR100689274B1 (en) * 2005-03-30 2007-03-08 김현기 Human primary cancer gene, protein encoded thereby
ES2477765T3 (en) 2005-04-19 2014-07-17 Seattle Genetics, Inc. Binding agents to humanized anti-cd70 and their uses
WO2006118308A1 (en) 2005-05-02 2006-11-09 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
AU2006255282A1 (en) 2005-06-03 2006-12-14 Aviaradx, Inc. Identification of tumors and tissues
WO2007030588A1 (en) 2005-09-07 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
JP2009513125A (en) * 2005-10-28 2009-04-02 ビオメリュー・ソシエテ・アノニム Cancer detection method
GB0526498D0 (en) * 2005-12-28 2006-02-08 Randox Lab Ltd Method
MX2008011356A (en) * 2006-03-03 2008-09-15 Veridex Llc Molecular assay to predict recurrence of dukes' b colon cancer.
GB0606954D0 (en) * 2006-04-06 2006-05-17 Randox Lab Ltd Method
AR053600A1 (en) * 2006-04-28 2007-05-09 Fundacion Inst Leloir AN ISOLATED DNA FRAGMENT FROM THE A33 HUMAN PROMOTER AND ITS USE TO DIRECT THE EXPRESSION OF A HETEROLOGICAL GENE IN TUMOR CELLS
WO2008024009A1 (en) * 2006-08-15 2008-02-28 Institut Molekulyarnoi Genetiki Rossiiskoi Akademii Nauk (Img Ran) Transcriptional level of a timp3 gene in the form of a diagnosis marker of a non-small cell carcinoma of lung
CA2656227A1 (en) * 2006-08-16 2008-03-13 Forerunner Pharma Research Co., Ltd. Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient
DK2061814T3 (en) 2006-10-27 2012-08-27 Genentech Inc Antibodies and immunoconjugates and their use.
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
US8822153B2 (en) 2007-06-01 2014-09-02 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
WO2008154249A2 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US20110230506A1 (en) * 2007-08-14 2011-09-22 Paul Delmar Predictive marker for egfr inhibitor treatment
EP2644711B1 (en) * 2007-10-23 2018-07-04 Clinical Genomics Pty Ltd A method of diagnosing neoplasms - II
US20110097271A1 (en) * 2008-02-11 2011-04-28 Hadasit Medical Research Services & Development Li Colon Cancer Associated Transcript 1 (CCAT1) As A Cancer Marker
DK2276509T3 (en) 2008-04-11 2016-09-19 Seattle Genetics Inc DETECTION AND TREATMENT OF CANCER IN PANCREAS, ovarian and other cancers
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
JP5606322B2 (en) 2008-10-20 2014-10-15 昇志 佐藤 Tumor antigen peptide and use thereof
WO2010062857A1 (en) 2008-11-26 2010-06-03 Allergan, Inc. Klk-13 antibody inhibitor for treating dry eye
WO2011009036A1 (en) * 2009-07-16 2011-01-20 Soymeds, Inc. Soybean derived human thyroglobulin, methods of producing and applications thereof
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
ES2874306T3 (en) 2010-09-29 2021-11-04 Agensys Inc Conjugates of antibodies and drugs (CAF) that bind to 191P4D12 proteins
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
EP3690063B1 (en) * 2014-11-25 2025-08-20 AIT Austrian Institute of Technology GmbH Diagnosis of lung cancer
JP2016214239A (en) * 2015-05-15 2016-12-22 国立大学法人高知大学 Pancreatic cancer marker
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
BR112021004670A2 (en) 2018-09-28 2021-06-01 President And Fellows Of Harvard College Cell reprogramming to reverse aging and promote organ and tissue regeneration
AU2019392090A1 (en) 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
TWI877278B (en) 2019-12-30 2025-03-21 美商思進公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5882874A (en) * 1998-02-27 1999-03-16 The Trustees Of Columbia University In The City Of New York Reciprocal subtraction differential display
WO1999050278A1 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Compositions and methods for the identification of lung tumor cells

Also Published As

Publication number Publication date
JP2004509612A (en) 2004-04-02
EP1358349A2 (en) 2003-11-05
CA2411601A1 (en) 2001-12-13
WO2001094629A8 (en) 2002-05-16
WO2001094629A2 (en) 2001-12-13
WO2001094629A3 (en) 2003-09-04
AU2001264559A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
AU2001264559A8 (en) Cancer gene determination and therapeutic screening using signature gene sets
AU2003215460A8 (en) Cancer associated protein kinases and their uses
AU3869400A (en) Human cancer associated gene sequences and polypeptides
IL167286A (en) Genetic analysis and authentication
AU5091201A (en) Vegf-modulated genes and methods employing them
EP1466982A4 (en) Pyroglutamyl peptidase and its gene
HUP0500041A3 (en) Oligonicleotide having 2'-o-(2-methoxyl)ethyl modifications and therapy using thereof
HUP0300005A3 (en) Modified cytokines for use in cancer therapy
AU2002303261A8 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
IL163900A0 (en) Genetic products differentially expressed in tumors and use thereof
MXPA03003011A (en) Methods of inducing cancer cell death and tumor regression.
AU2002356898A8 (en) Gene amplification and overexpression in cancer
AU2002342053A1 (en) Pancreatic cancer diagnosis and therapies
EP1427850A4 (en) Human toxicologically relevant genes and arrays
GB0326578D0 (en) Cancer diagnosis and therapy
GB0115780D0 (en) Therapeutic molecules and uses thereof
GB0226595D0 (en) Cancer therapy determination
AU2002366364A8 (en) E2f and cancer therapy
AU2002364077A8 (en) Gene expression profiles in stomach cancer
GB0020952D0 (en) Genes and proteins and their uses
AU2001288940A1 (en) Gene and sequence variation associated with cancer
AU2002305138A1 (en) Methods and materials for cancer treatment
GB0406539D0 (en) Gene therapy
GB0307739D0 (en) Hypermethylated genes and cervical cancer
GB0215773D0 (en) Compunds and their therapeutic use